儿童大环内酯类耐药肺炎支原体肺炎发生塑型性支气管炎的临床特征及危险因素分析

doi:10.12372/jcp.2026.25e1017

Abstract

Abstract:

Objective To investigate the clinical characteristics and risk factors for plastic bronchitis (PB) in children with macrolide-resistant Mycoplasma pneumoniae pneumonia (MRMPP). Methods A retrospective analysis was conducted on 156 children hospitalized with MRMPP in the Department of Respiratory between October 2023 and January 2024. Based on electronic bronchoscopy findings, patients were divided into a PB group (n=44) and a non-PB group (n=112). Clinical characteristics and laboratory indicators were compared between the two groups. Continuous variables showing statistical significance in univariate analysis were analyzed using receiver operating characteristic (ROC) curves to determine optimal cut-off values, which were then used to convert these variables into categorical variables. Independent risk factors were identified via multivariate binary logistic regression analysis. Results Univariate analysis revealed that the PB group had significantly higher incidences of pleural effusion, severe pneumonia, oxygen therapy support, as well as significantly longer hospitalization duration, older age, longer fever duration, and higher levels of C-reactive protein, procalcitonin, D-dimer, lactate dehydrogenase (LDH), and M. pneumoniae DNA in bronchoalveolar lavage fluid (BALF) compared to the non-PB group (all P<0.05). ROC curve analysis determined the optimal cut-off values for D-dimer, LDH, and BALF M. pneumoniae DNA to be 1.655 mg/L, 364.5 IU/mL, and 428500 copies/mL, respectively. Multivariate logistic regression analysis identified D-dimer>1.655 mg/L (OR=14.002, 95% CI: 4.063-48.251), LDH>364.5 IU/mL (OR=6.865, 95% CI: 2.251-20.933), and BALF M. pneumoniae DNA>428500 copies/mL (OR=12.306, 95% CI: 3.586-42.236) as independent risk factors for PB in MRMPP (all P<0.001). Conclusion Elevated levels of D-dimer, LDH, and M. pneumoniae DNA in BALF are independent risk factors for PB in children with MRMPP. Monitoring these indicators is crucial for the early identification of children at risk of developing PB.

Key words: Mycoplasma pneumoniae pneumonia, macrolide-resistant, plastic bronchitis, child

CLC Number:

NIU Yanhua, DONG Xiaoyan. Clinical characteristics and risk factors for plastic bronchitis in children with macrolide-resistant Mycoplasma pneumoniae pneumonia[J].Journal of Clinical Pediatrics, 2026, 44(2): 111-117.

Figures/Tables 4

Table 1

Table 2

Table 3

Table 4

References 37

[1]	中华人民共和国国家卫生健康委员会. 儿童肺炎支原体肺炎诊疗指南(2023年版)[J]. 国际流行病学传染病学杂志, 2023, 50(2): 79-85.
	National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of Mycoplasma pneumoniae pneumonia in children (2023 edition)[J]. Guoji Liuxingbingxue Chuanranbingxue Zazhi, 2023, 50(2): 79-85.
[2]	中华医学会儿科学分会呼吸学组, 中华儿科杂志编辑委员会, 中国医药教育协会儿科专业委员会. 儿童社区获得性肺炎管理指南(2024修订)[J]. 中华儿科杂志, 2024, 62(10): 920-930.
	The Subspecialty Group of Respiratory, the Society of Pediatrics, Chinese Medical Association the Editorial Board, Chinese Journal of Pediatrics. Guidelines for management of community-acquired pneumonia in children (2024 revision)[J]. Zhonghua Erke Zazhi, 2024, 62(10): 920-930.
[3]	Wang YS, Zhou YL, Bai GN, et al. Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children[J]. World J Pediatr, 2024, 20: 901-914. doi: 10.1007/s12519-024-00831-0
[4]	王玉屏, 卢美君, 黎瞳, 等. 珠海地区儿童急性下呼吸道肺炎支原体感染流行病学及肺炎支原体耐药基因检测的多中心调查与研究[J]. 中国医药科学, 2023, 13(14): 16-19.
	Wang YP, Lu MJ, Li T, et al. Multi-center investigation and research on epidemiology of children’s acute lower respiratory tract Mycoplasma pneumoniae infection and Mycoplasma pneumoniae drug resistance gene detection in Zhuhai area[J]. Zhongguo Yiyao Kexue, 2023, 13(14): 16-19.
[5]	王静, 吕海涛, 郑吉善. 2021—2024年宁波市某儿童医院耐药肺炎支原体与非细菌性病原体混合感染的流行病学特征分析[J]. 中华预防医学杂志, 2025, 59(03): 336-343.
	Wang J, Lyu HT, Zheng JS. Epidemiological characteristics of co-infection of drug-resistant Mycoplasma pneumoniae and non-bacterial pathogens in a children's hospital in Ningbo from 2021 to 2024[J]. Zhonghua Yufang Yixue Zazhi, 2025, 59(3): 336-343.
[6]	Li J, Liu L, Zhang H, et al. Severe problem of macrolides resistance to common pathogens in China[J]. Front Cell Infect Microbiol, 2023, 13: 1181633. doi: 10.3389/fcimb.2023.1181633
[7]	Yan C, Xue GH, Zhao HQ, et al. Current status of Mycoplasma pneumoniae infection in China[J]. World J Pediatr, 2024, 20(1): 1-4. doi: 10.1007/s12519-023-00783-x
[8]	郑宝英, 闫超, 薛冠华, 等. 耐药肺炎支原体肺炎患儿的临床特点及流行基因型特征分析[J]. 中华实用儿科临床杂志, 2017, 32(10): 735-739.
	Zheng BY, Yan C, Xue GH, et al. Analysis of clinical characteristics and epidemic genotypes of children with Mycoplasma pneumoniae pneumonia[J]. Zhonghua Shiyong Erke Linchuang Zazhi, 2017, 32(10): 735-739.
[9]	陈佳怡, 张晗, 尚云晓. 肺炎支原体肺炎支气管肺泡灌洗液中23S rRNA耐药基因阳性患儿的临床及支气管镜下特点[J]. 中华实用儿科临床杂志, 2022, 37(12): 897-902.
	Chen JY, Zhang H, Shang YX. Clinical and bronchoscopy characteristics of Mycoplasma pneumoniae pneumonia in children with 23S rRNA resistance gene positive in bronchoalveolar lavage fluid[J]. Zhonghua Shiyong Erke Linchuang Zazhi, 2022, 37(12): 897-902.
[10]	穆世茵, 邹映雪, 郭永盛, 等. 儿童重症肺炎支原体肺炎发生塑形性支气管炎的预测因素[J]. 中华儿科杂志, 2024, 62(9): 861-866.
	Mu SY, Zou YX, Guo YS, et al. Clinical characteristics and predictive factors for plastic bronchitis in children with severe Mycoplasma pneumoniae pneumonia[J]. Zhonghua Erke Zazhi, 2024, 62(9): 861-866.
[11]	Yang L, Zhang Y, Shen C, et al. Clinical features and risk factors of plastic bronchitis caused by Mycoplasma pneumoniae pneumonia in children[J]. BMC Pulm Med, 2023, 23(1): 468. doi: 10.1186/s12890-023-02766-0 pmid: 37996853
[12]	姚慧生, 刘立云, 伊丽丽, 等. 儿童重症肺炎支原体肺炎所致塑型性支气管炎的临床特点及危险因素分析[J]. 中国小儿急救医学, 2021, 28(8): 673-678.
	Yao HS, Liu LY, Yi LL, et al. Clinical characteristics and risk factors of plastic bronchitis caused by severe Mycoplasma pneumoniae pneumonia in children[J]. Zhongguo Xiaoer Jijiu Yixue, 2021, 28(8): 673-678.
[13]	姚慧生, 刘立云, 李淼, 等. 重症肺炎支原体肺炎所致塑型性支气管炎患儿多次支气管镜灌洗治疗的预测指标研究[J]. 国际儿科学杂志, 2024, 51(12): 849-853.
	Yao HS, Liu LY, Li M, et al. A clinical study of preditors of multiple bronchoscopic lavage therapy in children with plastic bronchitis due to severe Mycoplasma pneumoniae pneumonia[J]. Guoji Erkexue Zazhi, 2024, 51(12): 849-853.
[14]	Zhou Y, Zhang Y, Sheng Y, et al. More complications occur in macrolide-resistant than in macrolide-sensitive Mycoplasma pneumoniae pneumonia[J]. Antimicrob Agents Chemother, 2014, 58(2): 1034-1038. doi: 10.1128/AAC.01806-13
[15]	Chen YC, Hsu WY, Chang TH. Macrolide-resistant Mycoplasma pneumoniae infections in pediatric community-acquired pneumonia[J]. Emerg Infect Dis, 2020, 26(7): 1382-1391. doi: 10.3201/eid2607.200017
[16]	Ding W, Guo Y, Chen H, et al. Clinical features and risk factors for severe macrolide-resistant Mycoplasma pneumoniae pneumonia induced by 23 S rRNA A2063G mutation: a retrospective observational study[J]. Eur J Clin Microbiol Infect Dis, 2025, 44(10): 2475-2486. doi: 10.1007/s10096-025-05215-4
[17]	黎历, 梁明, 甄宏, 等. 耐大环内酯类肺炎支原体感染现状与耐药机制研究进展[J]. 中华实用儿科临床杂志, 2025, 40(7): 557-560.
	Li L, Liang M, Zhen H, et al. Current status of macrolide-resistant Mycoplasma pneumoniae infections and research progress on drug resis-tance mechanisms[J]. Zhonghua Shiyong Erke Linchuang Zazhi, 2025, 40(7): 557-560.
[18]	Feng M, Burgess AC, Cuellar RR, et al. Modelling persistent Mycoplasma pneumoniae biofilm infections in a submerged BEAS-2B bronchial epithelial tissue culture model[J]. J Med Microbiol, 2021, 70(1): 10.1099/jmm.0.00126.6.
[19]	Bose S, Segovia JA, Somarajan SR, et al. ADP-ribosylation of NLRP3 by Mycoplasma pneumoniae CARDS toxin regulates inflammasome activity[J]. mBio, 2014, 5(6): e02186-2114.
[20]	Segovia JA, Chang TH, Winter VT, et al. NLRP3 is a critical regulator of inflammation and innate immune cell response during Mycoplasma pneumoniae infection[J]. Infect Immun, 2017, 86(1): e00548-17.
[21]	华军. 儿童难治性肺炎支原体肺炎发生塑型性支气管炎的危险因素分析[J]. 中华实用儿科临床杂志, 2019, 34(16): 1219-1222.
	Hua J. Analysis of risk factors for plastic bronchitis in children with refractory Mycoplasma pneumoniae pneumonia[J]. Zhonghua Shiyong Erke Linchuang Zazhi, 2019, 34(16): 1219-1222.
[22]	徐颖, 钟科星, 刘喜, 等. 肺炎支原体肺炎合并塑型性支气管炎患儿D-二聚体和肝酶的变化及意义[J]. 中国小儿急救医学, 2025, 32(6): 443-448.
	Xu Y, Zhong KX, Liu X, et al. Changes and clinical significance of D-dimer and hepatic enzymes in children with Mycoplasma pneumoniae pneumonia complicated by plastic bronchitis[J]. Zhongguo Xiaoer Jijiu Yixue, 2025, 32(6): 443-448.
[23]	Huang JJ, Yang XQ, Zhuo ZQ, et al. Clinical characteristics of plastic bronchitis in children: a retrospective analysis of 43 cases[J]. Respir Res, 2022, 23(1): 51. doi: 10.1186/s12931-022-01975-1
[24]	Wang W, Wang L, Yin Z, et al. Correlation of DNA load, genotyping, and clinical. phenotype of Mycoplasma pneumoniae infection in children[J]. Front Pediatr, 2024, 12: 1369431. doi: 10.3389/fped.2024.1369431
[25]	劳洁娜, 钱玲鹤, 郎建伟. 肺炎支原体肺炎患儿支气管黏液栓形成的影响因素分析[J]. 中国妇幼保健, 2023, 38(24): 4893-4896.
	Lao JN, Qian LH, Lang JW. Analysis of influencing factors for bronchial mucus plug formation in children with Mycoplasma pneumoniae pneumonia[J]. Zhongguo Fuyou Baojian, 2023, 38(24): 4893-4896.
[26]	Liu J, Zhao F, Lu J, et al. High Mycoplasma pneumoniae loads and persistent long-term Mycoplasma pneumoniae DNA in lower airway associated with severity of pediatric Mycoplasma pneumoniae pneumonia[J]. BMC Infect Dis, 2019, 19(1): 1045. doi: 10.1186/s12879-019-4667-y
[27]	钟海琴, 殷荣, 蒋鲲, 等. 儿童肺泡灌洗液肺炎支原体DNA载量与免疫炎症指标的相关性分析[J]. 上海医学, 2024, 47(7): 428-432.
	Zhong HQ, Yin R, Jiang K, et al. Correlation between DNA load of Mycoplasma pneumoniae in bronchoalveolar lavage fluid and immune-inflammatory markers in children[J]. Shanghai Yixue, 2024, 47(7): 428-432.
[28]	Zhong HQ, Zeng ZY, Gu HX, et al. Effect of macrolide resistance and Mycoplasma pneumoniae DNA load in bronchoalveolar lavage fluid on immune and inflammatory responses in children with Mycoplasma pneumoniae pneumonia[J]. Indian Pediatr, 2025, 62: 893-898. doi: 10.1007/s13312-025-00190-7
[29]	方柯南, 王晶, 倪婧雯. 重症肺炎支原体肺炎患儿肺炎支原体DNA复制水平与病情的相关性[J]. 中国当代儿科杂志, 2019, 21(9): 876-880.
	Fang KN, Wang J, Ni JW. Correlation between Mycoplasma pneumoniae DNA replication level and disease severity in children with severe Mycoplasma pneumoniae pneumonia[J]. Zhongguo Dangdai Erke Zazhi, 2019, 21(9): 876-880.
[30]	朱美君. 儿童耐药肺炎支原体DNA拷贝量与临床预后相关性分析[J]. 临床肺科杂志, 2020, 25(3): 373-377.
	Zhu MJ. Analysis of correlation between DNA copy quantity and clinicalprognosis of drug-resistant Mycoplasma pneumoniae in children[J]. Linchuang Feike Zazhi, 2020, 25(3): 373-377.
[31]	Lu A, Wang C, Zhang X, et al. Lactate dehydrogenase as a biomarker for prediction of refractory Mycoplasma pneumoniae pneumonia in children[J]. Respir Care, 2015, 60(10): 1469-1475. doi: 10.4187/respcare.03920
[32]	刘建华, 刘金荣, 唐晓蕾, 等. 难治性肺炎支原体肺炎患儿遗留闭塞性支气管炎的预测因素分析[J]. 中华儿科杂志, 2023, 61(4): 317-321.
	Liu JH, Liu JR, Tang XL, et al. Predictive factors for sequelae of bronchitis obliterans in refractory Mycoplasma pneumoniae pneumonia[J]. Zhonghua Erke Zazhi, 2023, 61(4): 317-321.
[33]	Zhao L, Zhang T, Cui X, et al. Development and validation of a nomogram to predict plastic bronchitis in children with refractory Mycoplasma pneumoniae pneumonia[J]. BMC Pulm Med, 2022, 22(1): 253. doi: 10.1186/s12890-022-02047-2
[34]	Zhang J, Wang T, Li R, et al. Prediction of risk factors of bronchial mucus plugs in children with Mycoplasma pneumoniae pneumonia[J]. BMC Infect Dis, 2021, 21(1): 67. doi: 10.1186/s12879-021-05765-w
[35]	Shen F, Dong C, Zhang T, et al. Development of a nomogram for predicting refractory Mycoplasma pneumoniae pneumonia in children[J]. Front Pediatr, 2022, 10: 813614. doi: 10.3389/fped.2022.813614
[36]	Jin X, Zhu Y, Zhang Y, et al. Assessment of levels of D-dimer and interferon-γ in pediatric patients with Mycoplasma pneumoniae pneumonia and its clinical implication[J]. Exp Ther Med, 2018, 16(6): 5025-5030.
[37]	Kang B, Kim DH, Hong YJ, et al. Complete occlusion of the right middle cerebral artery associated with Mycoplasma pneumoniae pneumonia[J]. Korean J Pediatr, 2016, 59(3): 149-152. doi: 10.3345/kjp.2016.59.3.149 pmid: 27186223

变量	非PB组（n=112例）	PB组（n=44例）	χ²值	P
性别（男）	54(48.21）	20(45.45）	0.10	0.756
胸腔积液	38(33.93)	28(63.64)	11.42	<0.001
重症肺炎	89(79.46)	41(93.18)	4.28	0.039
氧疗支持	4(3.57)	8(18.18)	9.50	0.002
使用呼吸机	0(0.00）	2(4.55）	-	0.078^1）
肺不张	8(7.14)	6(13.64)	1.63	0.202

变量	非PB组（n=112例）	PB组（n=44例）	统计量	P
住院时长[M(P₂₅~P₇₅)]/d	6.00(6.00~7.00)	8.00(6.00~9.00)	Z=3.81	<0.001
年龄（$\bar{x}±s$±s）/月	89.10±31.10	100.43±28.81	t=2.16	0.038
入院时发热时长（$\bar{x}±s$）/d	5.86±2.09	7.09±2.13	t=3.22	0.002
总发热时长（$\bar{x}±s$）/d	6.40±2.15	8.39±2.28	t=4.96	<0.001
白细胞计数[M(P₂₅~P₇₅)]×10⁹·L^-1	7.53(5.71~10.13)	7.03(5.85~9.60)	Z=0.13	0.900
血小板计数[M(P₂₅~P₇₅)]×10⁹·L^-1	287.00(242.50~387.25)	297.00(236.00~351.00)	Z=0.07	0.943
C-反应蛋白[M(P₂₅~P₇₅)]/mg·L^-1	9.00(5.00~17.75)	13.50(5.25~30.25)	Z=2.24	0.025
PCT[M(P₂₅~P₇₅)]/ng·mL^-1	0.04(0.02~0.07)	0.06(0.03~0.09)	Z=2.29	0.022
D-二聚体[M(P₂₅~P₇₅)]/mg·L^-1	0.53(0.36~0.77)	1.93(0.71~3.06)	Z=5.78	<0.001
LDH[M(P₂₅~P₇₅)]/U·L^-1	345.00(295.75~423.50)	477.50(378.00~665.00)	Z=4.83	<0.001
IgE[M(P₂₅~P₇₅)]/IU·mL^-1	145.00（66.10~410.00）	286.00(39.70~670.25)	Z=0.47	0.635
BALF MP-DNA[M(P₂₅~P₇₅)]/copies· mL^-1	415 000(71 600~3 630 000)	3 705 000(811 500~8 850 000)	Z=3.24	0.001

检验变量	截断值	敏感度	特异性	AUC	P	95% CI
住院时长/d	7.5	0.545	0.764	0.688	<0.001	0.595~0.781
年龄/月	87.5	0.750	0.473	0.604	0.045	0.507~0.700
入院时发热时长/d	6.5	0.591	0.636	0.651	0.004	0.559~0.743
总发热时长/d	6.5	0.864	0.518	0.725	<0.001	0.641~0.809
CRP/mg·L^-1	18.5	0.409	0.791	0.614	0.027	0.515~0.714
PCT/ng·mL^-1	0.055	0.545	0.673	0.623	0.018	0.527~0.718
D-二聚体/mg·L^-1	1.655	0.591	0.927	0.796	<0.001	0.710~0.883
LDH/U·L^-1	364.5	0.864	0.600	0.750	<0.001	0.661~0.838
BALF MP-DNA/copies· mL^-1	428 500	0.841	0.500	0.665	0.001	0.571~0.759

影响因素	偏回归系数	标准误	χ²值	OR(95% CI)	P
D-二聚体>1.655 mg·L^-1	2.639	0.631	17.480	14.002(4.063~48.251)	<0.001
LDH>364.5 U·L^-1	1.926	0.569	11.469	6.865(2.251~20.933)	<0.001
BALF MP-DNA>428 500 copies·mL^-1	2.510	0.629	15.917	12.306(3.586~42.236)	<0.001
常量	-4.592	0.750	37.527	-	<0.001

Clinical characteristics and risk factors for plastic bronchitis in children with macrolide-resistant Mycoplasma pneumoniae pneumonia

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 37

Related Articles 15

Metrics

Comments

Recommended 0

[1]	LI Yun, GAO Hongbo, DI Yuqing, LI Longmin, LIU Haichun, ZHANG Xiaoyong, SHAO Yujun. Clinical characteristics and prognosis of metastatic pheochromocytoma and paraganglioma in children and adolescents [J]. Journal of Clinical Pediatrics, 2026, 44(2): 118-123.
[2]	LI Huarong, CHEN Chaoying, TU Juan, LIN Tiantian, WANG Nannan. Four cases of C3 glomerulopathy in children and literature review [J]. Journal of Clinical Pediatrics, 2026, 44(2): 139-145.
[3]	LI Ming, YUE Tong, WEN Min, WU Feifei, ZHANG Dan, XU Yingjie, KANG Min, ZHU Jia, YAN Yuchun, LAI Jianming, WU Fengqi. Clinical characteristics of Behcet syndrome with cardiovascular aneurysms in children [J]. Journal of Clinical Pediatrics, 2026, 44(2): 146-153.
[4]	LIANG Haodong, GUO Shengxuan, HU Siyuan, LU Xuanjun, ZHANG Yunhan, XU Chenxia. Research progress of the symptom scale for acute upper respiratory tract infection in children [J]. Journal of Clinical Pediatrics, 2026, 44(2): 161-166.
[5]	Subspecialty Pediatric Consensus Collaborative Group, Subspecialty Group of Infectious Diseases, Society of Pediatric, Chinese Medical Association, Subspecialty Group of Infectious Diseases, Society of Pediatric, Zhejiang Medical Association, National Clinical Research Center for Children and Adolescents' Health and Diseases. Expert consensus on the clinical application and individualized therapy of oxazolidinone antibiotics in children [J]. Journal of Clinical Pediatrics, 2026, 44(1): 1-16.
[6]	CHEN Dan, REN Jiaying, SUN Lifang, WEI Zhenghu, SUN Xiaomin. Clinical features and prognosis of severe Mycoplasma pneumoniae pneumonia combined with intracardiac thrombus in children: a single-center retrospective study [J]. Journal of Clinical Pediatrics, 2026, 44(1): 17-24.
[7]	LIU Min, WANG Qi, SU Jun, CUI Lidan, SUN Huixia, NING Wenhui. Clinical features, diagnosis, and treatment of Mycoplasma pneumoniae pneumonia secondary to infective endocarditis in children [J]. Journal of Clinical Pediatrics, 2026, 44(1): 25-30.
[8]	JIA Ru, MA Yan, YU Qun, LIU Haiping, LIU Ping. An analysis of influenza vaccine coverage and influencing factors among children under 16 years old in two suburban districts of Shanghai [J]. Journal of Clinical Pediatrics, 2026, 44(1): 31-37.
[9]	WU Jinjun, XIONG Hao, ZENG Hui, CHEN Zhi, YANG Li, SUN Ming, WANG Zhuo, DU Yu, QI Shanshan, WANG Wei, ZHANG Lannan. Clinical analysis of allogeneic hematopoietic stem cell transplantation on pediatric myeloid sarcoma [J]. Journal of Clinical Pediatrics, 2026, 44(1): 44-50.
[10]	LIANG Zhiru, GUO Linmei, WANG Fei, ZHAO Xiaoyun. Lupus enteritis or inflammatory bowel disease: a report of the diagnosis and treatment of systemic lupus erythematosus complicated with gastrointestinal symptoms [J]. Journal of Clinical Pediatrics, 2026, 44(1): 56-63.
[11]	ZHOU Yuanke, SUN Lina, FANG Ying. Research progress on the role of zinc in the occurrence, development and treatment of inflammatory bowel disease in children [J]. Journal of Clinical Pediatrics, 2026, 44(1): 64-70.
[12]	ZHANG Wenting, FENG Juan. Progress in pediatric Takotsubo syndrome [J]. Journal of Clinical Pediatrics, 2026, 44(1): 79-83.
[13]	ZHANG Wei, WANG Yang, DENG Wenhua, WU Yabin. Analysis of clinical manifestations, ciliary structure and genetic characteristics of primary ciliary dyskinesia in 14 children [J]. Journal of Clinical Pediatrics, 2025, 43(9): 680-685.
[14]	XIANG Linjuan, CHEN Xuexin, JIA Yanhui, WU Yuhang, CONG Xin, LI Wei, CHEN Yingying, CHEN Sun, HUANG Lisu. Prognostic factors analysis of adenovirus type 3 pneumonia in children [J]. Journal of Clinical Pediatrics, 2025, 43(9): 686-691.
[15]	WANG Jie, WU Bin, ZHANG Lannan, CHEN Kailan. Two cases of pediatric hepatosplenic T-cell lymphoma and literature review [J]. Journal of Clinical Pediatrics, 2025, 43(9): 698-704.